RESUMO
OBJECTIVES: Neisseria gonorrhoeae infections are the second most commonly reported disease in the United States and cause significant morbidity. We describe the prevalence of gonorrhea in a large sample of men tested for gonorrhea and Chlamydia trachomatis in Baltimore, Denver, San Francisco, and Seattle. METHODS: Gonorrhea prevalence was measured among 17,712 men tested in a variety of non-sexually transmitted disease (STD) clinic venues using urine-based nucleic acid amplification tests. RESULTS: Among 16,850 asymptomatic men, prevalence ranged from 0% to 1.5% by city (P=0.20): Baltimore 1.3%, Denver 1.5%, San Francisco 1.5%, and Seattle 0%. Among 862 symptomatic men, the gonorrhea prevalence varied from 0.0% to 28.3% by city (P<0.01). CONCLUSIONS: The high prevalence of gonorrhea in symptomatic men supports the importance of testing for symptomatic men. The prevalence of gonorrhea among asymptomatic men is low, and routine screening cannot be recommended when screening is performed for chlamydia, unless a substantial local prevalence of gonorrhea can be documented in specific targeted venues or population groups.
Assuntos
Infecções por Chlamydia/epidemiologia , Infecções por Chlamydia/prevenção & controle , Chlamydia trachomatis/isolamento & purificação , Gonorreia/epidemiologia , Gonorreia/prevenção & controle , Neisseria gonorrhoeae/isolamento & purificação , Adolescente , Adulto , Infecções por Chlamydia/etiologia , Infecções por Chlamydia/microbiologia , Feminino , Gonorreia/etiologia , Gonorreia/microbiologia , Humanos , Masculino , Programas de Rastreamento , Prevalência , Fatores de Risco , Estados Unidos/epidemiologia , Saúde da População UrbanaRESUMO
OBJECTIVE: The objective of this study was to measure the prevalence of Chlamydia trachomatis (CT) infection among men in clinical and nonclinical settings across the United States. GOAL: The goal of this study was to obtain data to inform recommendations regarding male CT screening. STUDY: The authors conducted a cross-sectional study of CT prevalence among adolescent and adult men in 4 U.S. cities (Baltimore, Denver, San Francisco, and Seattle). CT was detected using urine-based testing, and prevalence was calculated for first testing event. RESULTS: Over 23,000 men were tested for CT over a 3 1/2-year period. The majority (96%) were asymptomatic. Overall, prevalence was 7% and varied significantly between cities (range: Seattle, 1%; Baltimore, 12%), by age (peak prevalence at age 20-24 years, 9%), and between venues where CT testing was offered. CONCLUSIONS: At 7%, the prevalence of CT is moderately high among men opportunistically tested in nonclinical and clinical settings.
